Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
4(80.0%)
Phase 1
1(20.0%)
5Total
Phase 2(4)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT00738595Phase 2Completed

Phase II Study to Evaluate the Effectiveness of EVT 302 in Smoking Cessation.

Role: lead

NCT00622752Phase 2Completed

Effects of EVT 302 With or Without NRT on Craving and Withdrawal in Healthy Male Smokers Deprived of Cigarettes

Role: lead

NCT00526968Phase 1Completed

The Effects of a Novel NMDA NR2B-Subtype Selective Antagonist, EVT 101, on Brain Function

Role: lead

NCT00380003Phase 2Completed

Efficacy Study of EVT 201 to Treat Insomnia

Role: lead

NCT00401284Phase 2Completed

Efficacy Study of EVT 201 in the Treatment of Elderly Patients With Daytime Sleepiness

Role: lead

All 5 trials loaded